While drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with antiretrovirals, there are no published reports of bictegravir-induced DRESS. Bictegravir is recommended as first-line treatment for patients with HIV. Recognition of DRESS, its skin manifestations and potential complications is vital for appropriate care and management of acute HIV.